Our group have an approach driving projects to personalize cancer medicine and decipher tumor information into actionable knowledge.
One research focus relates to the interaction between cancer cells and their microenvironment, and how the tumor can circumvent the immunosurveillance, called immune editing, and the new line of immunotherapies directed against them, e.g. check-point inhibitors.